Cosmos Health (COSM) to Release Quarterly Earnings on Monday

Cosmos Health (NASDAQ:COSM) is projected to issue its results before the market opens on Monday, August 17th. Analysts expect Cosmos Health to post earnings of $0.01 per share and revenue of $19.42 million for the quarter.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.93 million. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%. On average, analysts expect Cosmos Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cosmos Health Price Performance

COSM stock opened at $0.23 on Monday. Cosmos Health has a 52 week low of $0.16 and a 52 week high of $1.32. The business has a 50-day simple moving average of $0.23 and a 200 day simple moving average of $0.32. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. The company has a market cap of $13.99 million, a PE ratio of -0.36 and a beta of 4.80.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cosmos Health has a consensus rating of “Sell”.

Insider Buying and Selling

In other news, CFO Georgios Terzis acquired 168,135 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $0.25 per share, with a total value of $42,033.75. Following the acquisition, the chief financial officer directly owned 2,235,398 shares in the company, valued at $558,849.50. The trade was a 8.13% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Grigorios Siokas acquired 349,825 shares of Cosmos Health stock in a transaction that occurred on Thursday, July 30th. The shares were purchased at an average price of $0.20 per share, for a total transaction of $69,965.00. Following the transaction, the chief executive officer directly owned 14,597,917 shares in the company, valued at $2,919,583.40. The trade was a 2.46% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 2,204,138 shares of company stock worth $457,137 in the last 90 days. Company insiders own 26.15% of the company’s stock.

Hedge Funds Weigh In On Cosmos Health

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd boosted its stake in shares of Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Cosmos Health by 260.5% in the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after buying an additional 241,775 shares during the period. Finally, Citadel Advisors LLC increased its stake in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after buying an additional 128,776 shares during the period. 12.61% of the stock is currently owned by institutional investors.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.